Cantor Fitzgerald forecasts Vaxcyte's EPS at $5.62

Summary

Brokerage firms have forecasted Vaxcyte, Inc.'s earnings for the fiscal year 2026, with Cantor Fitzgerald estimating earnings per share (EPS) at ($5.62) compared to the current consensus estimate of ($4.21). Several brokerage companies have given a positive rating to the stock, with an average ‘buy’ rating and a target price of $136.50. Vaxcyte’s stock opened at $37.20, and its market value is $4.8 billion. The company focuses on developing novel protein vaccines against bacterial infectious diseases, including its primary candidate, VAX-24.Market Beat

Impact Analysis

The event is classified at the company level, as the earnings forecast directly pertains to Vaxcyte, Inc. Cantor Fitzgerald’s prediction of a higher EPS ($5.62) than the consensus ($4.21) suggests increased revenue expectations, which can positively influence investor perception and potentially drive up stock prices. Historical context shows that the company had a negative EPS last year, indicating a significant turnaround or growth expectation.Market Beat+ 3 This optimistic earnings forecast, along with ‘buy’ ratings from major firms and a higher target price, may lead investors to view Vaxcyte as a promising investment opportunity. However, the current stock price of $37.20 suggests room for growth if the target price of $136.50 is met. Investors may consider buying opportunities, but they should also be aware of risks associated with maintaining such growth expectations, especially in the biotech sector.